{"filing":{"accession_number":"0001193125-26-270330","cik":"0001829802","ticker":"SNSE","company_name":"Sensei Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"d144622d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/d144622d8k.htm"},"events":[{"id":10926,"run_id":9584,"accession_number":"0001193125-26-270330","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Sensei Biotherapeutics appointed Anand Parikh as President and Chief Executive Officer (promoted from COO), Brian Stephenson as Chief Financial Officer, and Josiah Craver as Senior Vice President of Finance and principal accounting officer, all effective June 13, 2026. Additionally, Stephen M. Hahn and Saira Ramasastry were appointed as new directors on June 12, 2026. These appointments represent material changes to the company's executive and board leadership structure.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7372,"accession_number":"0001193125-26-270330","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses multiple executive appointments effective June 13, 2026: Anand Parikh as President and Chief Executive Officer (promoted from COO), Brian Stephenson as Chief Financial Officer, and Josiah Craver as Senior Vice President of Finance and principal accounting officer. The principal disclosed action centers on these individuals taking on new roles, with detailed compensation and severance arrangements. Additionally, two new directors (Stephen M. Hahn and Saira Ramasastry) were appointed on June 12, 2026. These are material changes to the company's leadership structure that would affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10927,"run_id":9584,"accession_number":"0001193125-26-270330","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.73,"summary":"The company amended its Certificate of Incorporation to change its name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc., with an associated ticker symbol change from SNSE to FTH, effective June 15, 2026. The name and symbol change was announced via press release and is material to investors as it affects company identification and trading.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7373,"accession_number":"0001193125-26-270330","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material amendment to the Certificate of Incorporation changing the company name from \"Sensei Biotherapeutics, Inc.\" to \"Faeth Therapeutics, Inc.\" and the associated ticker symbol change from SNSE to FTH. While this is a corporate name change (Item 5.03), it does not fit neatly into the more specific event categories (not a departure, appointment, compensation arrangement, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation). A company name change is material to investors as it affects identification and trading of the security, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7374,"accession_number":"0001193125-26-270330","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a company name change and ticker symbol change for Sensei Biotherapeutics, Inc., announced via press release on June 15, 2026. While name and symbol changes are administrative in nature, they are material to investors as they affect how the company is identified and traded in the market. This does not fit neatly into the more specific event categories (it is not an M\u0026A activity, executive change, financial restatement, or other defined event type), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10928,"run_id":9584,"accession_number":"0001193125-26-270330","anchor_item_number":"1.02","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"summary":"Sensei Biotherapeutics terminated its $50 million at-the-market (ATM) sales agreement with Jefferies, effective June 10, 2026. The agreement had never been utilized and its termination removes a future financing option rather than triggering an immediate financial obligation.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7371,"accession_number":"0001193125-26-270330","item_number":"1.02","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The filing discloses termination of a $50 million at-the-market (ATM) sales agreement with Jefferies, effective June 10, 2026. While Item 1.02 covers termination of material definitive agreements, the agreement was never utilized (no shares were sold), and its termination removes a future financing option rather than triggering an immediate financial obligation or material adverse event. This is a routine administrative disclosure of a terminated but unused financing facility.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10929,"run_id":9584,"accession_number":"0001193125-26-270330","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.95,"summary":"The company relocated its principal executive office from Rockville, Maryland to Austin, Texas, effective June 15, 2026. This is a routine administrative change of address and contact information.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7375,"accession_number":"0001193125-26-270330","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.95,"reasoning":"This disclosure reports a relocation of the company's principal executive office from Rockville, MD to Austin, TX, effective June 15, 2026. While the filing is required under Item 8.01 (Other Events), the relocation itself is a routine administrative matter—a change of address and contact information—that does not affect the company's financial condition, operations, or investor assessment materially. This is a standard housekeeping disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7371,"accession_number":"0001193125-26-270330","item_number":"1.02","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The filing discloses termination of a $50 million at-the-market (ATM) sales agreement with Jefferies, effective June 10, 2026. While Item 1.02 covers termination of material definitive agreements, the agreement was never utilized (no shares were sold), and its termination removes a future financing option rather than triggering an immediate financial obligation or material adverse event. This is a routine administrative disclosure of a terminated but unused financing facility.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15"},{"id":7372,"accession_number":"0001193125-26-270330","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses multiple executive appointments effective June 13, 2026: Anand Parikh as President and Chief Executive Officer (promoted from COO), Brian Stephenson as Chief Financial Officer, and Josiah Craver as Senior Vice President of Finance and principal accounting officer. The principal disclosed action centers on these individuals taking on new roles, with detailed compensation and severance arrangements. Additionally, two new directors (Stephen M. Hahn and Saira Ramasastry) were appointed on June 12, 2026. These are material changes to the company's leadership structure that would affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15"},{"id":7373,"accession_number":"0001193125-26-270330","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material amendment to the Certificate of Incorporation changing the company name from \"Sensei Biotherapeutics, Inc.\" to \"Faeth Therapeutics, Inc.\" and the associated ticker symbol change from SNSE to FTH. While this is a corporate name change (Item 5.03), it does not fit neatly into the more specific event categories (not a departure, appointment, compensation arrangement, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation). A company name change is material to investors as it affects identification and trading of the security, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15"},{"id":7374,"accession_number":"0001193125-26-270330","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a company name change and ticker symbol change for Sensei Biotherapeutics, Inc., announced via press release on June 15, 2026. While name and symbol changes are administrative in nature, they are material to investors as they affect how the company is identified and traded in the market. This does not fit neatly into the more specific event categories (it is not an M\u0026A activity, executive change, financial restatement, or other defined event type), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15"},{"id":7375,"accession_number":"0001193125-26-270330","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.95,"reasoning":"This disclosure reports a relocation of the company's principal executive office from Rockville, MD to Austin, TX, effective June 15, 2026. While the filing is required under Item 8.01 (Other Events), the relocation itself is a routine administrative matter—a change of address and contact information—that does not affect the company's financial condition, operations, or investor assessment materially. This is a standard housekeeping disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:17:16.580119+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-15"}]}